OBJECTIVE To determine correlates of human papillomavirus (HPV) vaccine acceptance for men. METHODS A convenience sample of men aged 18 to 45 years read a one-page information sheet about HPV and the HPV vaccine, then completed a 29-item questionnaire. chi(2) tests were used to determine whether differences in demographic, sexual, and vaccine-related variables existed between levels of wantin...

BACKGROUND The quadrivalent (types 6, 11, 16, and 18) human papillomavirus (HPV) L1 virus-like-particle vaccine was 95%-100% effective in preventing cervical and genital disease related to HPV-6, -11, -16, and -18. Vaccine efficacy is thought to be mediated by humoral immunity. Here, we analyze the effect of the baseline characteristics of subjects on vaccine-induced immune responses. METHODS...

BACKGROUND Targeted human papillomavirus (HPV) vaccine could prevent HPV-related cancers and genital warts among men who have sex with men (MSM). In order to develop effective vaccination programmes for MSM, it is crucial to understand their knowledge, beliefs about HPV and attitudes towards HPV vaccine. METHODS A systematic search of 10 databases examined articles investigating HPV knowledge...

The nation’s cancer status report in 2013 highlighted that cancers attributable to human papilloma virus (HPV) increased in the past decade, particularly cancers in the oropharynx and anus.1 HPV vaccine is crucial in reducing the burden of HPV-associated cancers, by protecting against HPV infections that cause cervical, vulvar, vaginal, anal and oropharyngeal cancers.2,3 Non-cancerous lesions, ...

BACKGROUND Human papillomavirus (HPV) vaccination was introduced into the routine immunization schedule in the United States in late 2006 for females aged 11 or 12 years, with catch-up vaccination recommended for those aged 13-26 years. In 2010, 3-dose vaccine coverage was only 32% among 13-17 year-olds. Reduction in the prevalence of HPV types targeted by the quadrivalent vaccine (HPV-6, -11, ...

BACKGROUND Given the variation in human papillomavirus (HPV) vaccine coverage across Canada, and debate regarding delivery of HPV vaccines in Catholic schools, we studied online comments on Canadian news websites to understand public perceptions of HPV and HPV vaccine. METHODS We searched English- and French-language Canadian news websites for 2012 articles that contained the terms "HPV" or "...

BACKGROUND Human papillomavirus (HPV) vaccination is recommended to protect against HPV-related diseases. OBJECTIVE To estimate HPV vaccine coverage and assess factors associated with vaccine awareness, initiation and receipt of 3 doses among women age 18-30 years. METHODS Data from the 2010 National Health Interview Survey were analyzed to assess associations of HPV vaccination among women...

UNLABELLED Background Men and women with HIV infection are at increased risk of developing cancers associated with human papillomavirus (HPV). The two licensed prophylactic HPV vaccines protect against de novo infection with HPV-16 and HPV-18, which cause the majority of HPV-associated cancers. Currently, no vaccine efficacy data are available for persons with HIV infection. Nevertheless, some ...

PURPOSE The Internet is an increasingly common source of health-related information. We sought to examine associations between parents' Internet information-seeking and their knowledge, attitudes and beliefs about human papillomavirus (HPV) vaccine. METHODS We interviewed parents within a year after approval of HPV vaccine for females and males. Participants were North Carolina parents with d...

PURPOSE To examine the policies state governments pursued and enacted across the United States in the 5-year period after the U.S. Food and Drug Administration licensed the human papillomavirus (HPV) vaccine in 2006, including the timing and number of bills introduced, the policies proposed, and the legislative success of HPV vaccine policy proposals. METHODS Content abstraction and analysis ...